Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Hyloris Pharmaceuticals SA
  6. News
  7. Summary
    HYL   BE0974363955

HYLORIS PHARMACEUTICALS SA

(HYL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hyloris Pharmaceuticals : Secures Licensing Deal for Rhoshan's Intravenous Acetylsalicylic Acid in US

10/13/2021 | 01:41am EST


ę MT Newswires 2021
All news about HYLORIS PHARMACEUTICALS SA
2021Hyloris Partners With Vaneltix Pharma to Develop, Commercialize Interstitial Cystitis P..
MT
2021Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in ..
AQ
2021Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in ..
CI
2021US FDA to Decide on Approval of Hyloris Painkiller Earlier Than Expected
MT
2021Hyloris Announces Earlier than Expected PDUFA Date for Maxigesic« IV
GL
2021Hyloris Announces Earlier than Expected PDUFA Date for Maxigesic? IV
CI
2021Hyloris Starts Strategic Partnership With Pleco Therapeutics
MT
2021Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute My..
AQ
2021Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute My..
CI
2021Pleco Therapeutics B.V. announced that it expects to receive ?1 million in funding from..
CI
More news
Financials
Sales 2021 2,65 M 2,95 M 2,95 M
Net income 2021 -13,0 M -14,5 M -14,5 M
Net cash 2021 42,0 M 46,8 M 46,8 M
P/E ratio 2021 -30,3x
Yield 2021 -
Capitalization 415 M 462 M 462 M
EV / Sales 2021 141x
EV / Sales 2022 35,4x
Nbr of Employees 8
Free-Float -
Chart HYLORIS PHARMACEUTICALS SA
Duration : Period :
Hyloris Pharmaceuticals SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HYLORIS PHARMACEUTICALS SA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 16,05 €
Average target price 17,75 €
Spread / Average Target 10,6%
EPS Revisions
Managers and Directors
Stijn van Rompay Chief Executive Officer & Executive Director
Jean-Luc Vandebroek Chief Financial Officer
Stefan Yee Chairman
Dietmar Aichhorn Chief Operating Officer
Marc Foidart Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HYLORIS PHARMACEUTICALS SA-7.23%462
JOHNSON & JOHNSON-0.28%449 095
ROCHE HOLDING AG-6.46%307 637
PFIZER, INC.-9.62%299 559
ABBVIE INC.0.42%240 379
NOVO NORDISK A/S-12.29%219 960